Physician profile
Jonathan D Powell
NPI 1386622819
$648.82
in general payments reported to CMS, 2019-2025
13 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.64 · 2021: $137 · 2022: $134 · 2023: $85.26 · 2024: $59.51 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $346.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $145.14 | 2023-2025 | |
| Baxter Healthcare | $94.08 | 2022 | |
| Welch Allyn | $94.08 | 2021 | |
| Alk-Abello, INC | $45.31 | 2025 | Neffy |
| Takeda Pharmaceuticals U.S.A., INC. | $43.33 | 2021-2022 | |
| Pfizer INC. | $42.40 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $41.44 | 2023-2024 | Vaxelis, Vaxneuvance, Proquad |
| Tris Pharma INC | $38.36 | 2019-2023 | Dyanavel Xr |
| Corium, LLC | $30.48 | 2025 | Azstarys |
| Noven Therapeutics, LLC | $24.05 | 2024 | Xelstrym |
| Kaleo, INC. | $19.02 | 2024 | Auvi-Q |
| Glaxosmithkline, LLC. | $17.21 | 2021 | |
| Shire North American Group INC | $13.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Powell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.